Factor Replacement Therapy for Hemophilia: How Infusions Are Given and Monitored

The kitchen table has become a small clinic. A father lays out an alcohol wipe, a butterfly needle and a vial of powder that will be mixed with sterile water in about a minute. His eight-year-old, who used to squeeze her eyes shut, now watches the line for air bubbles like a co-pilot. Nobody says anything dramatic. It is Tuesday, and Tuesday is an infusion day.

That ordinariness is, in a sense, the whole achievement. A generation ago, a child with severe hemophilia might spend weeks a year in hospital with swollen knees and elbows. Today most families learn to deliver treatment themselves, and the medical team’s job shifts from rescue toward measurement: how much factor is circulating, how often bleeds still happen, whether the immune system has started to fight the treatment.

This explainer walks through factor replacement therapy, how it works, how infusions are given, and what is actually being watched between visits. The decisions, always, belong to the person with hemophilia and the hematology team who know their history.

Factor replacement therapy: how it works in plain language

Blood clotting is a relay race. When a vessel is cut, more than a dozen proteins called clotting factors hand off signals to one another until a mesh of fibrin seals the leak. In hemophilia, one runner is missing or too weak to finish the leg. Hemophilia A means too little functional factor VIII; hemophilia B means too little factor IX. Both are inherited on the X chromosome, which is why the condition is far more common in males, although females can carry the gene and sometimes have low factor levels themselves (CDC).

Factor replacement therapy does something refreshingly literal. It supplies the missing protein, made either from donated human plasma or, more often now, by recombinant technology, which means cells in a laboratory are engineered to produce the human protein. Once infused into a vein, the factor circulates and joins the relay wherever a clot is trying to form.

The catch is that infused factor does not last. The body clears it over hours to days, so levels rise sharply after an infusion and then fall back toward the person’s own baseline. That rise and fall, sometimes called the sawtooth curve, is the central idea behind everything else in this article: when to infuse, how often, and what a blood test is really measuring.

Two broad strategies exist. On-demand treatment means infusing when a bleed happens. Prophylaxis, from the Greek for guarding in advance, means infusing on a regular schedule to keep factor levels high enough that most bleeds never start. Guideline bodies including the NHS and the CDC describe prophylaxis as the usual approach for severe hemophilia, particularly in children, because repeated joint bleeds cause permanent damage (NHS).

Which factor is replaced, and why severity changes the plan

Before any vial is opened, the team needs two pieces of information: which factor is low, and how low. Hemophilia A is roughly four times more common than hemophilia B; the CDC estimates hemophilia A occurs in about 1 in 5,000 male births and hemophilia B in about 1 in 25,000 (CDC). The two conditions look identical at the bedside, so a laboratory assay of factor activity settles the question.

Severity is defined by how much working factor a person makes on their own, expressed as a percentage of the normal level.

Severity	Baseline factor activity	Typical bleeding pattern	Common treatment approach
Severe	Less than 1% of normal	Spontaneous bleeds into joints and muscles, often without injury	Regular prophylaxis, usually started in early childhood
Moderate	1% to 5% of normal	Bleeds after minor injury; occasional spontaneous bleeds	Prophylaxis or on-demand, decided case by case
Mild	5% to 40% of normal	Bleeding mainly after surgery, dental work or significant trauma	Often on-demand; sometimes non-factor options

Severity categories follow the CDC classification (CDC). These bands guide, rather than dictate, the plan. Two people with the same baseline can bleed very differently depending on activity level, joint condition and how quickly they clear infused factor.

One practical consequence: a person with mild hemophilia A may go years between treatments and then need factor only around a tooth extraction, while a child with severe disease will be on a standing schedule from infancy. Both are receiving factor replacement therapy; the rhythm is simply different.

Hemophilia prophylaxis infusion vs on-demand treatment: what the evidence favors

If there is one thing worth having an opinion about in hemophilia care, it is this: bleeding into a joint is not a nuisance to be mopped up afterward. Blood is toxic to cartilage. Each bleed triggers inflammation of the joint lining, and repeated bleeds produce hemophilic arthropathy, a painful, stiff, permanently damaged joint. The NHS and Mayo Clinic both describe preventing these bleeds as the main reason prophylaxis is recommended for severe hemophilia (NHS; Mayo Clinic).

On-demand treatment still has a legitimate place. Someone with mild or moderate disease who rarely bleeds may be well served by treating episodes as they arise, and everyone on prophylaxis also needs an on-demand plan for breakthrough bleeds, injuries and procedures.

The distinction matters for monitoring, too. On-demand care is judged mainly by how quickly a bleed stops and whether the joint recovers fully. Prophylaxis is judged by what does not happen: the annual bleed count, the number of target joints (joints that have bled repeatedly), and how long factor levels stay above the person’s chosen protective floor.

Families often ask whether prophylaxis means a lifetime commitment. The honest answer is that plans are revisited. Growth, sport, a new job, pregnancy planning in carriers, or the arrival of a new treatment class can all prompt the team to adjust the approach. Starting prophylaxis is not a one-way door; it is a strategy that gets reviewed at clinic visits, typically at least once a year in comprehensive care programs (CDC).

Who is usually offered factor replacement, and who is asked to wait

Nearly everyone with a confirmed diagnosis of hemophilia A or B will use factor replacement at some point, if only around surgery or injury. The question the care team weighs is not so much whether, but on what schedule and with which product.

People usually offered regular prophylaxis include those with severe hemophilia, those with moderate disease who have had joint bleeds, anyone who has developed a target joint, and people in occupations or sports with high bleed risk. Infants with severe hemophilia are often started before or soon after the first joint bleed, because the CDC and NHS both note that early prophylaxis protects joints better than waiting for damage to appear (NHS).

Who tends to be asked to wait, or offered something else first?

• People with mild hemophilia A who respond to desmopressin, a synthetic hormone that releases the body’s own stored factor VIII, may not need factor products for minor bleeds. Response is tested in clinic before it is relied upon (Mayo Clinic).
• Someone with an active inhibitor may be steered toward bypassing agents or a non-factor therapy rather than standard replacement, because the antibody would neutralize the infused factor.
• A person with a suspected but unconfirmed diagnosis will usually complete testing first, since giving factor before the assay can muddy the result.
• Very young infants without a reliable vein may begin with on-demand treatment while the team plans safe long-term access.

None of these are refusals; they are sequencing decisions. The treating hematologist balances bleed risk, vein access, family circumstances and the person’s own goals, and the plan is written down in a treatment letter that the family can carry to any emergency department.

How a factor VIII infusion at home actually happens, step by step

Watch an experienced family and the whole thing takes about fifteen minutes, most of it hand-washing and setup. The steps are the same for factor IX. Here is what the teaching sessions cover, described so that you know what to expect, not as a substitute for the training itself.

• Preparation. The factor arrives as a freeze-dried powder in a vial, stored as the label directs, often refrigerated. The person checks the expiry, gathers supplies and washes hands thoroughly.
• Reconstitution. Sterile water is transferred into the powder vial using a supplied device. The vial is rolled gently, never shaken, until the solution is clear. Shaking can damage the protein.
• Drawing up. The dissolved factor is pulled into a syringe. Air bubbles are tapped out.
• Vein access. A tourniquet goes on, a vein is chosen, the skin is cleaned, and a small butterfly needle is inserted. A flash of blood in the tubing confirms placement.
• Slow push. The factor is injected over a few minutes at the rate the team has advised. A slow push reduces vein irritation and lets the person stop if anything feels wrong.
• Finish and record. The needle is withdrawn, pressure applied, and the batch number, date and reason for the infusion are logged.

That last step matters more than it sounds. Infusion logs, whether paper or app-based, are the raw data the clinic uses to judge whether the schedule is working. The NHS describes home treatment as standard once a person or caregiver has completed training with the hemophilia team (NHS). Nobody is expected to learn this alone, and most centers ask families to demonstrate the technique several times under supervision before going solo.

Ports, PICC lines and small veins: getting factor into a child

The single biggest practical obstacle in pediatric hemophilia is not the medicine; it is the vein. A toddler’s veins are tiny, mobile and attached to a person who does not want to sit still. Comprehensive care teams spend considerable energy on this problem, and there are three broad solutions.

Peripheral veins. Many children manage with a butterfly needle in the hand, arm or foot from the start. Numbing cream, warm compresses to dilate veins, distraction and a calm, predictable routine all help. Child life specialists in hospital programs often coach families on positioning and language that lowers anxiety.

Central venous access devices. A port is a small reservoir placed under the skin of the chest during a short surgical procedure, connected to a catheter that sits in a large vein. Infusions are given through the skin into the port with a special needle. Ports make frequent infusions far easier but carry their own risks, chiefly infection and clot formation in the catheter, which is why teams weigh them carefully and remove them once peripheral access becomes reliable (Cleveland Clinic).

PICC lines. A peripherally inserted central catheter enters at the arm and threads to a central vein. It is generally a shorter-term option, for example around surgery or during intensive treatment for an inhibitor.

Comfort is a clinical outcome here, not a soft extra. A child who associates infusion with panic is a child whose family may skip doses. Teams therefore treat needle fear seriously, and many children who begin with a port are infusing into their own arm veins by the age they start school. The timeline varies widely and is decided jointly with the family.

How often is factor replacement given? Half-life explained

The frequency of prophylaxis comes down to one word: half-life. A drug’s half-life is the time it takes for the body to clear half of what was given. Standard factor VIII has a shorter half-life than standard factor IX, so people with hemophilia A on conventional products generally need more frequent infusions than people with hemophilia B. Both the NHS and CDC note that standard prophylaxis typically involves infusions several times a week (NHS; CDC).

Extended half-life products change the math. These are factor molecules chemically modified, for instance by attaching a polyethylene glycol chain or fusing the factor to another protein, so the body clears them more slowly. The result is fewer infusions to maintain the same protective floor, or a higher floor with the same number of infusions. The CDC lists both standard and extended half-life products among current treatment options (CDC).

Half-life is also personal. Two adults with severe hemophilia A can clear the same product at noticeably different rates because of body weight, age, blood group and other factors. This is why modern clinics often perform pharmacokinetic testing, a series of blood samples after an infusion that maps an individual’s own clearance curve. The schedule is then built around that curve rather than a population average.

What this means for a reader: the specific number of infusions per week is not a fixed property of hemophilia. It is an output of product choice, individual clearance, activity level and the protective floor the person and their team have agreed on. Those parameters, and any changes to them, sit with the prescribing hematologist.

How treatment is monitored: factor levels, trough tests and bleed diaries

Monitoring in hemophilia is less about a single dramatic test and more about assembling a picture from several small ones.

Factor activity assays. A blood sample is tested for how much clotting activity the missing factor provides, expressed as a percentage of normal. Taken at the lowest point before the next scheduled infusion, this is the trough level, and it tells the team whether the protective floor is holding. Taken shortly after an infusion, it shows the peak and confirms the product is being absorbed and not neutralized.

Pharmacokinetic profiling. Multiple samples over a day or more map the person’s own clearance curve, as described above. Results feed into schedule decisions.

Inhibitor screening. A specific test, the Bethesda assay, measures whether antibodies are inactivating infused factor. The CDC recommends regular inhibitor testing, particularly in the early years of treatment when risk is highest (CDC).

Bleed and infusion records. The annualized bleeding rate, meaning the number of treated bleeds per year, is the headline outcome in most clinical trials and in clinic. A rising count, or a bleed that recurs in the same joint, is a signal to look again at the plan.

Joint assessment. Physiotherapists score range of motion, swelling and muscle strength using structured tools, and imaging such as ultrasound or MRI may be used to detect early joint changes before they cause symptoms.

General health screening. Liver tests, viral screening and, in adults, cardiovascular and bone health checks are part of comprehensive annual review (Johns Hopkins Medicine).

Put together, these tell the team three things: is the factor getting where it needs to go, is it being neutralized, and are the joints staying healthy. Any one result in isolation is rarely the full story.

What are inhibitors in hemophilia, and how are they found?

An inhibitor is an antibody the immune system makes against infused clotting factor. To the immune system, a protein the body has never produced can look foreign, and it responds the way it would to a virus: by building antibodies that bind and inactivate it. The infused factor then disappears from the bloodstream far faster than expected, or does not work at all.

Inhibitors are the most serious complication of factor replacement. The CDC reports that about one in five people with hemophilia A develop an inhibitor at some point, with the risk highest during the first several dozen exposures to factor, which usually means early childhood (CDC). Inhibitors are less common in hemophilia B but can be accompanied by allergic reactions when they do occur.

How are they detected? Sometimes the clue is clinical: a bleed that does not respond to the usual treatment, or a child whose bleeds increase despite regular prophylaxis. More often, an inhibitor is picked up on routine screening before anyone notices a change. The Bethesda assay reports a titer, a number describing how much antibody is present. Low-titer inhibitors may be overcome by adjusting factor treatment; high-titer inhibitors generally require a different strategy.

That strategy has two arms. Bypassing agents are products that promote clotting through routes that do not depend on the missing factor, used to treat bleeds. Immune tolerance induction is a program of frequent, regular factor exposure designed to teach the immune system to accept the protein; it can take many months to years and requires close monitoring (CDC). Non-factor therapies, discussed next, have added a third option for prevention. All of these decisions are made by the specialist team, often with input from a national inhibitor registry.

Alternatives and newer approaches: non-factor therapy and gene therapy

Factor replacement is no longer the only tool, and it is worth understanding the alternatives in neutral terms so that conversations with the care team make sense.

Bispecific antibodies. For hemophilia A, an engineered antibody (emicizumab is the generic name) mimics the job of factor VIII by holding two other clotting factors together so the relay can continue. It is given as an injection under the skin rather than into a vein, and because it is not factor VIII, existing inhibitors do not neutralize it. The CDC and Mayo Clinic list this class among current treatment options for people with and without inhibitors (CDC; Mayo Clinic). Monitoring differs: standard factor assays are unreliable in people on this therapy, so the laboratory uses modified tests, and factor is still needed for surgery and breakthrough bleeds.

Rebalancing agents. A newer class works by dampening the body’s natural anticoagulant proteins so that even a small amount of clotting activity can form a stable clot. These are given by subcutaneous injection and are monitored with specialized assays.

Gene therapy. A single infusion delivers a working copy of the factor gene to liver cells using a modified virus that cannot replicate. Factor production can rise for years, though levels vary between people and may decline over time; eligibility criteria are strict, and liver monitoring is intensive in the months afterward (CDC).

Adjuncts. Desmopressin for responsive mild hemophilia A, and antifibrinolytic medicines (tranexamic acid is one generic) that slow clot breakdown, are commonly used for mouth and nose bleeds and dental work (NHS).

None of these replaces the treating team’s judgment about who is a candidate. Each has its own monitoring requirements, and most people using them still keep factor on hand.

What the first weeks and months on factor replacement usually look like

Starting or restructuring prophylaxis has a recognizable arc, though the pace varies with age, vein access and how quickly a family feels confident.

The first visits. Baseline blood work confirms factor levels and screens for inhibitors. The team explains the product, the planned schedule and the emergency plan. For children, a decision about vein access is made or scheduled. Families receive a treatment letter and learn how to record infusions.

Weeks one to several. Early infusions are often given in clinic so nurses can observe technique and watch for reactions. Teaching sessions for home infusion begin, usually with the caregiver practicing reconstitution first and vein access later. The NHS describes this training as a standard part of care before independent home treatment (NHS).

The first few months. Trough and possibly peak levels are checked to confirm the schedule is delivering the intended floor. Inhibitor testing is repeated, since the CDC notes risk is highest during early exposures (CDC). Bleed diaries are reviewed; any breakthrough bleed prompts a conversation rather than alarm.

By the first annual review. A full comprehensive assessment brings together hematology, physiotherapy, nursing and often social work. Joint scores, growth in children, bleed counts and quality-of-life questions all feed into whether the plan continues unchanged or is adjusted.

Through all of this, the day-to-day feels increasingly routine, which is the goal. Expect the clinic to remain closely involved for the first year of a new regimen and to loosen the frequency of contact only when the data, and the family, are settled.

Risks and side effects of factor infusions, described plainly

Factor replacement is a well-established treatment, and most infusions pass without incident. Honest counseling still covers the following.

Inhibitor development. Discussed above, this is the most consequential risk, affecting roughly one in five people with hemophilia A over their lifetime according to the CDC (CDC). It is monitored for, not prevented outright.

Allergic and infusion reactions. Hives, flushing, chest tightness or wheeze can occur, more often in hemophilia B and particularly when an inhibitor is emerging. Early infusions of a new product are typically given where staff can respond, and families are taught what a reaction looks like.

Vein and access problems. Bruising, phlebitis (an inflamed vein) and scarring at frequently used sites are common minor issues. Ports carry risks of infection and catheter clots that need prompt attention (Cleveland Clinic).

Blood-borne infection. This is largely a historical concern. Plasma-derived products today undergo donor screening and viral inactivation, and recombinant products contain no human blood. The CDC notes that no cases of HIV or hepatitis C transmission through clotting factor have been documented in the United States since current safety measures were introduced (CDC).

Thrombosis. Very rare with replacement therapy itself; more relevant with bypassing agents or when non-factor therapies are combined with them, which is why combinations are managed carefully.

Balanced against these is the risk of not treating: progressive joint destruction, life-threatening bleeds into the brain or throat, and the school and work absences that follow. The care team’s role is to lay both columns side by side for each individual.

What people often get wrong about factor replacement therapy

Myth: a bump on the head or a nosebleed is the main danger. External bleeds are visible and frightening, but joint and muscle bleeds cause most long-term disability, and intracranial bleeding is the most dangerous acute event. Prophylaxis is aimed primarily at the bleeds you cannot see (Mayo Clinic).

Myth: people with hemophilia bleed faster. They do not. They bleed for longer, because the clot that forms is fragile. A cut on the finger is usually manageable with pressure; a bleed deep in the calf is not.

Myth: once you are on prophylaxis, you cannot bleed. Prophylaxis raises the floor; it does not build a ceiling. Breakthrough bleeds happen, especially just before the next scheduled infusion when levels are lowest, and everyone on prophylaxis needs an on-demand plan.

Myth: factor products still carry the infection risks of the 1980s. Modern screening, viral inactivation and recombinant manufacturing have changed this picture completely, as the CDC documents (CDC).

Myth: a normal factor level after infusion means an inhibitor is impossible. Low-titer inhibitors can coexist with reasonable peak levels while shortening how long factor lasts. Only the specific antibody assay, alongside recovery testing, tells the full story.

Myth: exercise should be avoided. Strong muscles protect joints. Comprehensive care teams generally encourage regular, lower-impact activity and help families choose sports sensibly rather than avoiding movement (CDC).

Myth: gene therapy means never needing factor again. Factor expression after gene therapy varies and can fall over time; people are advised to keep factor available and remain under specialist follow-up (CDC).

Questions to ask your care team about factor replacement

A comprehensive clinic visit moves quickly. Bringing a short written list keeps the conversation anchored on what matters to you. These are the questions experienced families and adults tend to find most useful.

• Which factor am I missing, what is my baseline level, and how does that shape the plan you are proposing?
• Is prophylaxis or on-demand treatment being recommended for me, and what evidence or personal history is that based on?
• What protective trough level are we aiming for, and how will we know whether we are reaching it?
• Would a pharmacokinetic study help personalize my schedule, and what would it involve?
• How often will I be screened for inhibitors, and what would happen if one were found?
• What is my on-demand plan for a breakthrough bleed, and what is the plan for an injury when I am away from home?
• How will vein access be managed, and if a port is suggested, what are the trade-offs and the plan for eventually removing it?
• Who trains me or my child for home infusion, how many supervised sessions are typical, and who do I call if a session at home goes wrong?
• How should infusions be recorded, and how will the team use those records at review?
• Are non-factor therapies or gene therapy relevant to my situation, and what monitoring would they require instead?
• How should I prepare for dental work, surgery or a planned pregnancy?
• What should my school, employer or sports coach know, and can you provide a treatment letter for emergencies?

No single visit will answer all of these. Comprehensive care programs typically review the full picture at least annually, so unanswered items can be carried forward rather than rushed (CDC). Any decision about starting, adjusting or stopping a regimen rests with the prescribing hematologist working alongside you.

When to call your doctor: red-flag signs during factor replacement

Most bleeds in a well-managed person are handled at home according to the written plan. Some situations should never wait. Call emergency services or go directly to an emergency department, and infuse factor first if your plan says to do so, for any of the following (MedlinePlus; NHS):

• Any head injury, even a minor one, or a severe or unusual headache, vomiting, confusion, drowsiness, weakness on one side or a seizure. Bleeding inside the skull can develop hours after a bump.
• Neck or throat swelling, difficulty swallowing or breathing, or a hoarse voice after injury.
• Severe abdominal pain, black or bloody stools, or vomiting blood.
• A bleed into the hip, groin or forearm with tingling, numbness or a cold, pale hand or foot, which can signal pressure on nerves or blood vessels.
• Signs of an allergic reaction during or shortly after an infusion: hives, facial swelling, wheeze, chest tightness or faintness. Stop the infusion and seek help immediately.
• A bleed that has not improved after the treatment your plan specifies, or that keeps returning to the same joint.
• Fever, redness, pain or pus around a port or catheter site, which may indicate infection.
• Any serious injury or road traffic collision, regardless of visible bleeding.

Contact your hemophilia team, rather than emergency services, when bleeds are becoming more frequent, when you have run out of or have doubts about your supply, when you are due surgery or dental work, or when you have any question about whether to give an extra infusion. The written treatment letter from your center should travel with you and be shown to any clinician who does not know your history. When in doubt about severity, teams consistently prefer to be called early rather than late.

Frequently asked questions

How does factor replacement therapy work in hemophilia?

It supplies the clotting protein a person cannot make enough of, either factor VIII or factor IX, by infusing it into a vein. The protein then circulates and takes its place in the clotting cascade so a stable clot can form. Because the body clears infused factor over hours to days, the effect is temporary, which is why regular preventive infusions or treatment at the time of a bleed are needed, as described by the CDC and NHS.

How often is factor replacement given for prophylaxis?

It depends on the factor involved, the product’s half-life and the individual’s own clearance rate. Standard factor VIII generally needs more frequent infusions than standard factor IX, and extended half-life products reduce frequency further. Many clinics now measure a person’s pharmacokinetic profile and tailor the schedule to it. The exact frequency is set and adjusted by the treating hematologist rather than being a fixed feature of the condition.

Can a factor VIII infusion be done at home?

Yes. Home infusion by the person with hemophilia or a trained caregiver is standard practice in comprehensive care programs once formal training with the hemophilia team is complete, according to the NHS. Training covers hand hygiene, reconstituting the powder, drawing up, accessing a vein or port, infusing slowly and recording each infusion. Centers usually observe several supervised infusions before independent home treatment begins.

What are inhibitors in hemophilia and how are they detected?

Inhibitors are antibodies the immune system produces against infused clotting factor, making the treatment less effective or ineffective. The CDC reports about one in five people with hemophilia A develop one, most often during early exposures in childhood. They are detected with a blood test called the Bethesda assay, performed on a regular schedule and whenever a bleed fails to respond as expected. Management options include bypassing agents, immune tolerance induction and non-factor therapies.

What is a trough level and why does it matter?

A trough level is the amount of clotting factor activity in the blood at its lowest point, just before the next scheduled infusion. It indicates the protective floor a prophylaxis plan is maintaining. If the trough is lower than intended, breakthrough bleeds become more likely toward the end of each interval. Teams use trough results alongside bleed records and joint assessments to decide whether a schedule needs adjusting.

Is prophylaxis better than on-demand treatment?

For severe hemophilia, guideline bodies including the NHS and CDC describe regular prophylaxis as the usual recommendation because it prevents the joint bleeds that cause permanent damage. On-demand treatment remains appropriate for some people with mild or moderate disease who bleed rarely. Everyone on prophylaxis also needs an on-demand plan for injuries and breakthrough bleeds. The choice is individualized by the hematology team.

Do children with hemophilia need a port for infusions?

Not always. Many children manage with peripheral veins using numbing cream, distraction and a consistent routine. A port, a small device placed under the skin of the chest, is considered when frequent infusions are needed and veins are unreliable. Ports ease access but carry risks of infection and catheter clots, so teams plan to remove them once peripheral infusion becomes practical, often around school age, though timing varies by child.

Are factor products safe from viruses like HIV and hepatitis?

Current products are considered very safe. Plasma-derived factor undergoes donor screening and viral inactivation steps, and recombinant factor is made in laboratory cell lines without human blood. The CDC states that no cases of HIV or hepatitis C transmission through clotting factor have been documented in the United States since these safety measures were introduced. Historical infections from the 1980s do not reflect today’s supply.

What are the alternatives to factor replacement therapy?

Options listed by the CDC and Mayo Clinic include bispecific antibody therapy for hemophilia A, which mimics factor VIII and is injected under the skin; rebalancing agents that dampen natural anticoagulants; gene therapy delivering a working factor gene to liver cells; desmopressin for responsive mild hemophilia A; and antifibrinolytic medicines for mouth and nose bleeds. Each has distinct eligibility criteria and monitoring needs, and factor is still typically kept on hand.

When should someone on factor replacement go to the emergency department?

Immediately for any head injury or unusual headache, neck or throat swelling, breathing difficulty, severe abdominal pain, black or bloody stools, numbness or coldness in a limb after a bleed, signs of an allergic reaction during infusion, or a bleed that fails to respond to the written plan. MedlinePlus and the NHS emphasize that intracranial bleeding can develop hours after a minor bump, so early assessment is preferred.

References

• CDC: Treatment of Hemophilia
• CDC: About Hemophilia
• NHS: Haemophilia – Treatment
• MedlinePlus: Hemophilia

This article is for general information only and is not a substitute for professional medical advice. Please consult a qualified doctor about your individual situation.